Characterization of human FHL2 transcript variants and gene expression regulation in hepatocellular carcinoma

Gene

Volumn 481, Issue 1, 2011, Pages 41-47

  Ng, Chor Fung ^a   Zhou, Wayne Jun Wei ^a   Ng, Patrick Kwok Shing ^a   Li, Man Shan ^a   Ng, Yuen Keng ^a   Lai, Paul Bo San ^a   Tsui, Stephen Kwok Wing ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

FHL2; Liver cancer; Promoter; Splice variants; Transcription factor binding sites

Indexed keywords

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; BINDING SITE; COMPUTER MODEL; DNA FLANKING REGION; FHL2 GENE; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; METHYLATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

5' FLANKING REGION; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MUSCLE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 79957641495     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.04.005     Document Type: Article

References (28)

1. Bach I. The LIM domain: regulation by association. Mech. Dev. 2000, 91:5-17.
2. Cartharius K., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
3. Chan K.K., et al. Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 1998, 210:345-350.
4. Chen D., et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res. 2003, 63:6626-6634.
5. Chu P.H., Bardwell W.M., Gu Y., Ross J., Chen J. FHL2 (SLIM3) is not essential for cardiac development and function. Mol. Cell. Biol. 2000, 20:7460-7462.
6. Ding L., et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J. Clin. Invest. 2009, 119:349-361.
7. Du X., Hublitz P., Gunther T., Wilhelm D., Englert C., Schule R. The LIM-only coactivator FHL2 modulates WT1 transcriptional activity during gonadal differentiation. Biochim. Biophys. Acta 2002, 1577:93-101.
8. Fimia G.M., De Cesare D., Sassone-Corsi P. A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol. Cell. Biol. 2000, 20:8613-8622.
9. Gabriel B., et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res. 2004, 24:921-927.
10. Genini M., Schwalbe P., Scholl F.A., Remppis A., Mattei M.G., Schafer B.W. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol. 1997, 16:433-442.
11. Guo Z., et al. Sp1 upregulates the four and half lim 2 (FHL2) expression in gastrointestinal cancers through transcription regulation. Mol. Carcinog. 2010, 49:826-836.
12. Heemers H.V., Regan K.M., Dehm S.M., Tindall D.J. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res. 2007, 67:10592-10599.
13. Hill A.A., Riley P.R. Differential regulation of Hand1 homodimer and Hand1-E12 heterodimer activity by the cofactor FHL2. Mol. Cell. Biol. 2004, 24:9835-9847.
14. Johannessen M., Moller S., Hansen T., Moens U., Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci. 2006, 63:268-284.
15. Kel A.E., Gossling E., Reuter I., Cheremushkin E., Kel-Margoulis O.V., Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res. 2003, 31:3576-3579.
16. Labalette C., Renard C.A., Neuveut C., Buendia M.A., Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol. Cell. Biol. 2004, 24:10689-10702.
17. Li H.Y., et al. Protein-protein interaction of FHL3 with FHL2 and visualization of their interaction by green fluorescent proteins (GFP) two-fusion fluorescence resonance energy transfer (FRET). J. Cell. Biochem. 2001, 80:293-303.
18. Morgan M.J., Madgwick A.J. Slim defines a novel family of LIM-proteins expressed in skeletal muscle. Biochem. Biophys. Res. Commun. 1996, 225:632-638.
19. Morlon A., Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc. Natl. Acad. Sci. U S A 2003, 100:3977-3982.
20. Muller J.M., et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 2000, 19:359-369.
21. Philippar U., et al. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol. Cell 2004, 16:867-880.
22. Purcell N.H., Darwis D., Bueno O.F., Muller J.M., Schule R., Molkentin J.D. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol. Cell. Biol. 2004, 24:1081-1095.
23. Scholl F.A., McLoughlin P., Ehler E., de Giovanni C., Schafer B.W. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J. Cell Biol. 2000, 151:495-506.
24. Stenger J.E., et al. Statistical Viewer: a tool to upload and integrate linkage and association data as plots displayed within the Ensembl genome browser. BMC Bioinformatics 2005, 6:95.
25. Stilo R., Leonardi A., Formisano L., Di Jeso B., Vito P., Liguoro D. TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett. 2002, 521:165-169.
26. Tanahashi H., Tabira T. Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum. Mol. Genet. 2000, 9:2281-2289.
27. Yan J., Zhu J., Zhong H., Lu Q., Huang C., Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett. 2003, 553:183-189.
28. Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005, 24:1021-1032.